Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 25 04:00PM ET
4.68
Dollar change
-0.27
Percentage change
-5.42
%
Index- P/E- EPS (ttm)-4.17 Insider Own23.63% Shs Outstand5.16M Perf Week-14.13%
Market Cap25.23M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.12M Perf Month-24.15%
Income-21.62M PEG- EPS next Q- Inst Own2.08% Short Float0.52% Perf Quarter-37.30%
Sales0.34M P/S74.19 EPS this Y- Inst Trans-83.90% Short Ratio0.82 Perf Half Y2.81%
Book/sh-0.07 P/B- EPS next Y- ROA-46.68% Short Interest0.02M Perf Year-29.52%
Cash/sh4.88 P/C0.96 EPS next 5Y- ROE-231.11% 52W Range3.45 - 8.56 Perf YTD0.95%
Dividend Est.- P/FCF- EPS past 5Y20.93% ROI-74.41% 52W High-45.33% Beta1.62
Dividend TTM- Quick Ratio6.05 Sales past 5Y-25.35% Gross Margin18.48% 52W Low35.70% ATR (14)0.41
Dividend Ex-Date- Current Ratio6.05 EPS Y/Y TTM42.14% Oper. Margin-6647.51% RSI (14)33.25 Volatility8.13% 7.74%
Employees134 Debt/Eq- Sales Y/Y TTM93.75% Profit Margin-6339.59% Recom3.00 Target Price24.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q33.60% Payout- Rel Volume0.28 Prev Close4.95
Sales Surprise- EPS Surprise- Sales Q/Q-18.39% EarningsFeb 05 Avg Volume26.00K Price4.68
SMA20-17.48% SMA50-17.60% SMA200-12.66% Trades Volume7,348 Change-5.42%
Jun-18-24 06:30AM
Jun-06-24 06:45AM
May-20-24 07:00AM
May-02-24 07:00AM
Apr-08-24 07:00AM
02:52PM Loading…
Apr-03-24 02:52PM
Mar-28-24 07:15AM
Mar-27-24 07:00AM
Mar-21-24 07:00AM
Mar-19-24 04:00AM
Mar-14-24 07:00AM
Mar-11-24 07:00AM
Mar-06-24 07:00AM
Feb-28-24 07:00AM
Feb-12-24 05:20PM
02:00AM Loading…
Jan-23-24 02:00AM
Jan-08-24 07:00AM
Dec-21-23 07:00AM
Nov-13-23 07:29PM
Aug-16-23 07:00AM
Jul-13-23 02:00AM
Jul-12-23 11:17AM
Jul-11-23 02:00AM
Apr-27-23 07:00AM
Mar-13-23 08:00AM
Dec-22-22 07:00AM
Dec-15-22 04:05PM
Nov-10-22 07:00AM
Oct-31-22 08:00AM
Sep-29-22 07:00AM
07:00AM Loading…
Sep-06-22 07:00AM
Apr-07-22 07:00AM
Apr-01-22 07:00AM
Mar-31-22 07:00AM
Mar-28-22 07:00AM
Mar-23-22 07:00AM
Mar-17-22 07:00AM
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.